Showing posts with label Uveal melanoma. Show all posts
Showing posts with label Uveal melanoma. Show all posts

Tuesday, 27 January 2026

Radiowave-Assisted Iridocyclectomy for Anterior Uveal Melanoma: A 13-Year Clinical Study | Chapter 11 | Medical Science: Updates and Prospects Vol. 4

 

Background: Uveal melanoma is a highly malignant tumour of the eye, which is characterised by melanocytic tumour growth within the uveal tract of the eye. There is a nearly equal distribution of primary uveal melanoma gender. The management options include transpupillary thermotherapy, brachytherapy, stereotactic radiotherapy, limited surgical resection, enucleation and orbital exenteration. Complications in the surgical removal of pre-equatorial tumours are largely technique-related and may be reduced by combining tumour resection with simultaneous vessel coagulation using radiowave surgery.

 

Purpose: The aim of this study is to determine the efficacy of resecting iris and ciliary body melanoma with the use of a 3.8-4.0-Mhz radiowave surgery unit.

 

Methods: This study was carried out at the Department of Eye Cancer, the Filatov Institute, between 2005 and 2018 and included 45 patients with iris and ciliary body melanoma, with a mean age of 56.3 ± 2.2 years and a slight predominance of female patients (53.3%). Sixty-seven patients who had undergone iridociliary melanoma excision using a conventional technique with cutting tools were used as retrospective controls. The eye examination included visual acuity measurement, perimetry, biomicroscopy and ophthalmoscopy. Tumour, nodus и metastasis (TNM) staging was according to the American Joint Committee on Cancer (AJCC). No metastases were seen at the time of enrollment. The mean tumour prominence at baseline was 4.0 ± 0.3 mm, with a mean base diameter of 8.3 ± 0.4 mm, corresponding to a tumour volume of  34.3 ± 0.7 mm3. Patients in both groups were stratified by baseline visual acuity into two subgroups (0.1–0.5 and 0.6–0.8). In the study group, subgroup 1A included 37 patients (82.2%) with visual acuity of 0.1–0.5, while subgroup 1B comprised 8 patients (17.8%) with visual acuity of 0.6–0.8, and in the retrospective control group, subgroup 2A consisted of 55 patients (82.1%) with visual acuity of 0.1–0.5, and subgroup 2B included 12 patients (17.9%) with visual acuity of 0.6–0.8 (p > 0.05). The analysis was performed by analysis of variance (ANOVA) using Statistica 13.0 (Dell Statsoft Inc., Austin, TX).

 

Results: The radiosurgical approach to treatment of iridociliary tumours in our patients allowed significantly reducing the rates of intraoperative and postoperative complications (χ2=4.16; df=1; p=0.04). In addition, the rates of intraoperative and postoperative complications for the treatment of iridociliary tumours with cutting instruments were 9.1% and 10.4%, respectively. The use of a radiowave surgery unit for uveal melanoma resection allowed preserving baseline visual acuity in all patients, with a tumour recurrence rate of not more than 2.2%.

 

Conclusion: The use of a radiowave surgery unit for uveal melanoma resection allowed preserving baseline visual acuity in all patients. Early (12-month) treatment outcomes (visual functions and postoperative clinical course) and late treatment outcomes (visual functions; optic media; IOP; and tumour recurrence) for iridociliary melanoma resection using a radiowave 3.8-4.0 MHz unit allow us to state that high-frequency radiowave surgery enables reducing the risk of intraoperative and postoperative complications and, consequently, preserving a good visual function.

 

 

Author(s) Details

Maletskyy Anatoliy Parfentievic
Filatov Institute of Eye Diseases and Tissue Therapy, National Academy of Medical Sciences of Ukraine, Odesa, Ukraine.

 

Khomiakova Olena Victorovna
Filatov Institute of Eye Diseases and Tissue Therapy, National Academy of Medical Sciences of Ukraine, Odesa, Ukraine.

 

Please see the book here :- https://doi.org/10.9734/bpi/msup/v4/6842

Saturday, 13 September 2025

Intraocular Melanoma: Current and Emerging Treatment Strategies | Book Publisher International

 

Intraocular tumors occupy an important place among neoplasms of the eye, second in frequency after eyelid tumors.

 

Due to their high malignancy, uveal melanomas pose a threat both directly to the visual organ and to the patient's life itself.

 

It should be noted that in most cases (75%) uveal melanomas affect people of working age, and most often they are diagnosed at the age of 31 - 60 years.

 

Thus, the problem of developing new and improving existing methods of treating patients with uveal melanomas of the eye has not only scientific and applied, but also medical and social significance.

 

Currently, instead of the previously used enucleation of the eyeball, the emphasis is on organ-preserving treatment of uveal melanoma, the advantage of which is not only in preserving the eye, but also preserving vision in many patients. This is especially important for melanoma in the only sighted eye. Radiation therapy, laser therapy, new methods of intraocular surgery, chemotherapy, immunotherapy and their combination are used.

 

Also, in recent years, a large amount of information has accumulated in oncology, indicating a significant role of disorders of the mechanisms of immunological control in the initiation and development of the tumour process. This primarily concerns the suppression of the functional activity of immunocompetent cells, in particular T-dependent lymphocytes and mononuclear phagocytes in malignant tumours of various localisations, which was taken into account by us when developing an additional treatment method using alpha-2b-interferon (laferobion).

 

In this work, based on our own experience of practice in ophthalmic oncology for more than 45 years, we draw the attention of ophthalmic oncologists to the need for a systemic approach to the treatment of intraocular melanoma. In addition to traditional treatment methods, we have included alpha-2b-interferon (laferobion) (taking into account the body's antitumor resistance), selective intra-arterial chemotherapy in the treatment method to increase the sensitivity of tumor cells to local radiation therapy, as well as our own surgical developments in intraocular tumor excision using a radiowave knife (primarily for melanomas of the iris, ciliary body and preequatorial part of the choroid) and the method of high-frequency electric welding (choroidal melanoma). Our goal was to expand the indications for organ-preserving treatment of intraocular melanomas and reduce the percentage of surgical and postoperative complications. In our opinion, the work we have carried out and the results presented in the book may be of interest to ophthalmologists.

Author(s) Details:-

 

Anatoliy Parfentievich Maletskyy
State University "Institute of Eye Diseases and Tissue Therapy named after Filatov, V. P. National Academy of Sciences of Ukraine", Odessa, Ukraine.

 

Liudmila Mykolaivna Velichko
State University "Institute of Eye Diseases and Tissue Therapy named after Filatov, V. P. National Academy of Sciences of Ukraine", Odessa, Ukraine.

 

Mykola Mykolaiiovich Umanets
State University "Institute of Eye Diseases and Tissue Therapy named after Filatov, V. P. National Academy of Sciences of Ukraine", Odessa, Ukraine.

 

Olena Victorovna Khomyakova
State University "Institute of Eye Diseases and Tissue Therapy named after Filatov, V. P. National Academy of Sciences of Ukraine", Odessa, Ukraine.

 

Natalia Mikhilivna Bigun
Regional Clinical Hospital, Ukraine.

 

Yevhenii Andriiovich Chumakov
State University "Institute of Eye Diseases and Tissue Therapy named after Filatov, V. P. National Academy of Sciences of Ukraine", Odessa, Ukraine.

 

Please see the book here:- https://doi.org/10.9734/bpi/mono/978-81-992493-8-7